PD-1 inhibitors

Phase 2Small molecule

BBioNTech US Inc.

PD-1 inhibitors is one of 202 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

201

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaActive, not recruiting

Intrahepatic CholangiocarcinomaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

MelanomaActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Nasopharyngeal CarcinomaPhase 2

Active, not recruiting

Intrahepatic CholangiocarcinomaPhase 2

Active, not recruiting

Metastatic Colorectal CancerPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPreclinical

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

MelanomaPreclinical

Active, not recruiting

Hepatocellular CarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Trodelvy

Gilead

Preclinical

37 2

PD-1 inhibitors

BBioNTech US Inc.

Phase 2

1 3

Zolymbus

AbbVie

Preclinical

1 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 5

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 6

Acupan

YYonsei University

Preclinical

1 7

Chantix

PPrism Pharmaceuticals

Preclinical

1 8

Paracetamol

GSK

Preclinical

1 9

Apatinib Mesylate

BBukwang Pharmaceutical

Preclinical

3 10

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

N/ARecruiting

Hepatocellular Carcinoma

NCT06740370

Not yet recruiting

Advanced

NCT07466225

Q4 2026

Phase 1Recruiting

Low Dose Radiotherapy

NCT05615142

Q2 2027

Not yet recruiting

Advanced NSCLC

NCT06496009

Phase 2Not yet recruiting

Metastatic Colorectal Cancer

NCT06835179

Q3 2027

Phase 2Recruiting

Recurrent or Metastatic NPC

NCT06472713

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma5 trials

TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT

Completed·YYunfei Yuan··NCT05535998·743 enrolled

Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation

Recruiting·CChen Xiaoping·N/A·NCT06248554·200 enrolled

Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma

Not yet recruiting·TTongji Hospital··NCT07379489·300 enrolled

Show 2 more trials

PD-1 Inhibitor Combined With 125I Seed Implantation for Hepatocellular Carcinoma's Extrahepatic Metastasis: Efficacy and Safety

Completed·JJiangxi Provincial Cancer Hospital·N/A·NCT06991907·80 enrolled

TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma

Recruiting·SSun Yat-sen University·N/A·NCT06740370·32 enrolled

PD-1 Inhibitors3 trials

Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC

Completed·HHunan Cancer Hospital··NCT06031376·106 enrolled

High- and Low-dose Radiotherapy Combined With PD-1 Inhibitors for MSS CRLM

Unknown status·JJiangsu Cancer Institute & Hospital·Phase 1·NCT06045286·30 enrolled

HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT

Completed·PPeking University·Phase 2·NCT05166239·66 enrolled

Melanoma2 trials

A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma

Terminated·BBioNTech US Inc.·Phase 1·NCT04625205·22 enrolled

Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma

Active, not recruiting·IInstitute of Oncology Ljubljana·N/A·NCT07428252·150 enrolled

PD-1antibody2 trials

PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC

Unknown status·SSun Yat-sen University·Phase 3·NCT05737563·380 enrolled

The Immune Assessment of PD-1 Antibody Therapy in Tumor

Recruiting·QQuanli Gao··NCT06693440·3,000 enrolled

Non-Small Cell Lung Cancer2 trials

Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer

Active, not recruiting·PPeking University People's Hospital··NCT07359040·80 enrolled

Survival Analysis and Prognostic Biomarker Exploration of Postoperative Adjuvant Therapy Patterns in Patients With Non-small Cell Lung Cancer After Neoadjuvant Immunotherapy

Active, not recruiting·—··NCT07256002·10,000 enrolled

11 more indications

Nasopharyngeal Carcinoma2 trials

PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial

Unknown status·SSichuan Cancer Hospital and Research Institute·Phase 2·NCT05520814·50 enrolled

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

Recruiting·MMing-Yuan Chen·Phase 2·NCT07070479·208 enrolled

Low Dose Radiotherapy1 trial

Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.

Recruiting·SSichuan University·Phase 1·NCT05615142·9 enrolled

Intrahepatic Cholangiocarcinoma1 trial

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05913661·30 enrolled

Advanced Biliary Tract Carcinoma1 trial

Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract Carcinoma

Unknown status·TThe First Hospital of Jilin University·Phase 2·NCT05509478·46 enrolled

Advanced1 trial

HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion

Not yet recruiting·PPeking University··NCT07466225·150 enrolled

Advanced NSCLC1 trial

The Clinical Characteristics and Efficacy of Immunotherapy in First-line PD-L1-negative Advanced NSCLC Patients

Not yet recruiting·SShanghai Pulmonary Hospital, Shanghai, China··NCT06496009·845 enrolled

Metastatic Colorectal Cancer1 trial

SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06835179·28 enrolled

Postoperative Adjuvant Therapy1 trial

Postoperative Adjuvant Therapy of HCC Based on PD-1

Completed·CChen Xiaoping··NCT05307926·573 enrolled

Neoadjuvant Immunotherapy1 trial

Proposal of a Novel Model for Identifying Complete Response in dMMR Colon Cancer Following Neoadjuvant Immunotherapy

Completed·SSun Yat-sen University··NCT06980350·156 enrolled

Recurrent or Metastatic NPC1 trial

Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC

Recruiting·MMing-Yuan Chen·Phase 2·NCT06472713·32 enrolled

Breast Cancer1 trial

Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer

Recruiting·SShandong Cancer Hospital and Institute·Phase 2·NCT06802757·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 26 trial records for PD-1 inhibitors. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PD-1 inhibitors compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PD-1 inhibitors. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioNTech US Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBioNTech US Inc.

PD-1 inhibitors

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q2 2027

Q3 2027

Trials by Indication[1]

Hepatocellular Carcinoma5 trials

PD-1 Inhibitors3 trials

Melanoma2 trials

PD-1antibody2 trials

Non-Small Cell Lung Cancer2 trials

Nasopharyngeal Carcinoma2 trials

Low Dose Radiotherapy1 trial

Intrahepatic Cholangiocarcinoma1 trial

Advanced Biliary Tract Carcinoma1 trial

Advanced1 trial

Advanced NSCLC1 trial

Metastatic Colorectal Cancer1 trial

Postoperative Adjuvant Therapy1 trial

Neoadjuvant Immunotherapy1 trial

Recurrent or Metastatic NPC1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News